BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, Roessner A. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia. 2004;6:529-535. [PMID: 15548361 DOI: 10.1593/neo.04178] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Sindi IA, Babalghith AO, Tayeb MT, Mufti AH, Naffadi H, Ekram SN, Elhawary EN, Alenezi M, Elhawary NA. Risk of Colorectal Carcinoma May Predispose to the Genetic Variants of the GST, CYP450, and TP53 Genes Among Nonsmokers in the Saudi Community. Int J Gen Med 2021;14:1311-23. [PMID: 33883929 DOI: 10.2147/IJGM.S294802] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Elshazli RM, Toraih EA, Elgaml A, Kandil E, Fawzy MS. Genetic polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal cancer risk: An updated meta-analysis based on 59 case-control studies. Gene 2020;734:144391. [PMID: 32001373 DOI: 10.1016/j.gene.2020.144391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
3 Gunaratna RT, Santos A, Luo L, Nagi C, Lambertz I, Spier M, Conti CJ, Fuchs-Young RS. Dynamic role of the codon 72 p53 single-nucleotide polymorphism in mammary tumorigenesis in a humanized mouse model. Oncogene 2019;38:3535-50. [PMID: 30651598 DOI: 10.1038/s41388-018-0630-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
4 López-Nieva P, Fernández-Navarro P, Vaquero-Lorenzo C, Villa-Morales M, Graña-Castro O, Cobos-Fernández MÁ, López-Lorenzo JL, Llamas P, González-Sanchez L, Sastre I, Pollan M, Malumbres M, Santos J, Fernández-Piqueras J. RNA-Seq reveals the existence of a CDKN1C-E2F1-TP53 axis that is altered in human T-cell lymphoblastic lymphomas. BMC Cancer 2018;18:430. [PMID: 29661169 DOI: 10.1186/s12885-018-4304-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
5 Tian X, Dai S, Sun J, Jiang S, Jiang Y. The association between the TP53 Arg72Pro polymorphism and colorectal cancer: An updated meta-analysis based on 32 studies. Oncotarget 2017;8:1156-65. [PMID: 27901479 DOI: 10.18632/oncotarget.13589] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
6 Zhang A, Shi TY, Zhao Y, Xiang J, Yu D, Liang Z, Xu C, Zhang Q, Hu Y, Wang D, He J, Duan P. No association between TP53 Arg72Pro polymorphism and ovarian cancer risk: evidence from 10113 subjects. Oncotarget 2017;8:112761-9. [PMID: 29348863 DOI: 10.18632/oncotarget.22603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
7 do Espírito Santo GF, Galera BB, Duarte EC, Chen ES, Azis L, Damazo AS, Saba GT, de Sousa Gehrke F, Guerreiro da Silva IDC, Waisberg J. Prognostic significance of vascular endothelial growth factor polymorphisms in colorectal cancer patients. World J Gastrointest Oncol 2017; 9(2): 78-86 [PMID: 28255429 DOI: 10.4251/wjgo.v9.i2.78] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
8 Basu S, Murphy ME. Genetic Modifiers of the p53 Pathway. Cold Spring Harb Perspect Med 2016;6:a026302. [PMID: 27037420 DOI: 10.1101/cshperspect.a026302] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 5.8] [Reference Citation Analysis]
9 Volodko N, Salla M, Eksteen B, Fedorak RN, Huynh HQ, Baksh S. TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development. World J Gastroenterol 2015; 21(36): 10358-10366 [PMID: 26420962 DOI: 10.3748/wjg.v21.i36.10358] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
10 Vymetalkova V, Soucek P, Kunicka T, Jiraskova K, Brynychova V, Pardini B, Novosadova V, Polivkova Z, Kubackova K, Kozevnikovova R, Ambrus M, Vodickova L, Naccarati A, Vodicka P. Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes. PLoS One 2015;10:e0134463. [PMID: 26226484 DOI: 10.1371/journal.pone.0134463] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
11 Mahmood S, Sivoňová M, Matáková T, Dobrota D, Wsólová L, Dzian A, Mištuna D. Association of EGF and p53 gene polymorphisms and colorectal cancer risk in the Slovak population. Open Medicine 2014;9:405-16. [DOI: 10.2478/s11536-013-0300-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Zhang P, Mirani N, Baisre A, Fernandes H. Molecular Heterogeneity of Head and Neck Squamous Cell Carcinoma Defined by Next-Generation Sequencing. The American Journal of Pathology 2014;184:1323-30. [DOI: 10.1016/j.ajpath.2014.01.028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
13 Singamsetty GK, Malempati S, Bhogadhi S, Kondreddy R, Govatati S, Tangudu NK, Govatati S, kuraganti AK, Bhanoori M, Kassetty K. TP53 alterations and colorectal cancer predisposition in south Indian population: A case-control study. Tumor Biol 2014;35:2303-11. [DOI: 10.1007/s13277-013-1305-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
14 Dahabreh IJ, Schmid CH, Lau J, Varvarigou V, Murray S, Trikalinos TA. Genotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: a systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancer. Am J Epidemiol 2013;177:1317-25. [PMID: 23729685 DOI: 10.1093/aje/kws394] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
15 Lajin B, Alhaj Sakur A, Alachkar A. Association between polymorphisms in apoptotic genes and susceptibility for developing breast cancer in Syrian women. Breast Cancer Res Treat 2013;138:611-9. [PMID: 23468244 DOI: 10.1007/s10549-013-2467-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
16 Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, Vodicka P. Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer. Mutagenesis 2012;27:211-8. [PMID: 22294769 DOI: 10.1093/mutage/ger067] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 6.3] [Reference Citation Analysis]
17 Ognjanovic S, Martel G, Manivel C, Olivier M, Langer E, Hainaut P. Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma. Sarcoma 2012;2012:492086. [PMID: 22550420 DOI: 10.1155/2012/492086] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
18 Liu L, Wang K, Zhu ZM, Shao JH. Associations between P53 Arg72Pro and development of digestive tract cancers: a meta-analysis. Arch Med Res 2011;42:60-9. [PMID: 21376265 DOI: 10.1016/j.arcmed.2011.01.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
19 Wang JJ, Zheng Y, Sun L, Wang L, Yu PB, Dong JH, Zhang L, Xu J, Shi W, Ren YC. TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis. Mol Biol Rep 2011;38:4847-53. [PMID: 21140221 DOI: 10.1007/s11033-010-0619-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
20 Taneja P, Maglic D, Kai F, Zhu S, Kendig RD, Fry EA, Inoue K. Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clin Med Insights Oncol 2010;4:15-34. [PMID: 20567632 DOI: 10.4137/cmo.s4773] [Cited by in Crossref: 64] [Cited by in F6Publishing: 73] [Article Influence: 5.3] [Reference Citation Analysis]
21 Tang NP, Wu YM, Wang B, Ma J. Systematic review and meta-analysis of the association between P53 codon 72 polymorphism and colorectal cancer. Eur J Surg Oncol. 2010;36:431-438. [PMID: 20363586 DOI: 10.1016/j.ejso.2010.03.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
22 Souček K, Gajdušková P, Brázdová M, Hýžd'alová M, Kočí L, Vydra D, Trojanec R, Pernicová Z, Lentvorská L, Hajdúch M, Hofmanová J, Kozubík A. Fetal colon cell line FHC exhibits tumorigenic phenotype, complex karyotype, and TP53 gene mutation. Cancer Genetics and Cytogenetics 2010;197:107-16. [DOI: 10.1016/j.cancergencyto.2009.11.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
23 Godai TI, Suda T, Sugano N, Tsuchida K, Shiozawa M, Sekiguchi H, Sekiyama A, Yoshihara M, Matsukuma S, Sakuma Y, Tsuchiya E, Kameda Y, Akaike M, Miyagi Y. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy. BMC Cancer 2009;9:420. [PMID: 19954513 DOI: 10.1186/1471-2407-9-420] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
24 Katkoori VR, Jia X, Shanmugam C, Wan W, Meleth S, Bumpers H, Grizzle WE, Manne U. Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res 2009;15:2406-16. [PMID: 19339276 DOI: 10.1158/1078-0432.CCR-08-1719] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 4.2] [Reference Citation Analysis]
25 Zhu ZZ, Liu B, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, Zhu GS. Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression. J Zhejiang Univ Sci B 2008;9:847-52. [PMID: 18988302 DOI: 10.1631/jzus.B0820100] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
26 Wegman PP, Marcus NJ, Malakkaran BP, Wingren S. Biological significance of allele specific loss of the p53 gene in breast carcinomas. Breast Cancer Res Treat 2009;118:15-20. [PMID: 18853251 DOI: 10.1007/s10549-008-0212-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
27 Zhu ZZ, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, Zhu G. Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol. 2007;37:385-390. [PMID: 17599946 DOI: 10.1093/jjco/hym034] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
28 Zawlik I, Kita D, Vaccarella S, Mittelbronn M, Franceschi S, Ohgaki H. Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. Brain Pathol 2009;19:188-94. [PMID: 18462472 DOI: 10.1111/j.1750-3639.2008.00170.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
29 Poehlmann A, Kuester D, Meyer F, Lippert H, Roessner A, Schneider-Stock R. K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract. 2007;203:489-497. [PMID: 17629419 DOI: 10.1016/j.prp.2007.06.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 4.6] [Reference Citation Analysis]
30 Mitra S, Banerjee S, Misra C, Singh RK, Roy A, Sengupta A, Panda CK, Roychoudhury S. Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population. J Clin Pathol. 2007;60:1040-1047. [PMID: 17079356 DOI: 10.1136/jcp.2005.034835] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
31 Lima JM, Serafim PV, Silva ID, Forones NM. [Role of the genetic polymorphism of p53 (codon 72) gene in colorectal cancer]. Arq Gastroenterol 2006;43:8-13. [PMID: 16699611 DOI: 10.1590/s0004-28032006000100005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
32 Pérez LO, Abba MC, Dulout FN, Golijow CD. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006; 12(9): 1426-1429 [PMID: 16552814 DOI: 10.3748/wjg.v12.i9.1426] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
33 Rehemtulla A, Ross BD. A review of the past, present, and future directions of neoplasia. Neoplasia 2005;7:1039-46. [PMID: 16354585 DOI: 10.1593/neo.05793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
34 Galic V, Willner J, Wollan M, Garg R, Garcia R, Goff BA, Gray HJ, Swisher EM. Common polymorphisms inTP53 andMDM2 and the relationship toTP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosom Cancer 2007;46:239-47. [DOI: 10.1002/gcc.20407] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
35 Rehemtulla A, Ross BD. Coming of Age in the Life of Neoplasia. Neoplasia 2004;6:691-6. [DOI: 10.1593/neo.6-6ed] [Reference Citation Analysis]